The aging population is especially prone to a number of neurological conditions, including dementia associated with cerebrovascular disease, called vascular dementia, and Alzheimer Disease. Serge Gauthier, MD, FRCPC, is a neurologist and CIHR/R&D Senior Scientist, who has been conducting research on dementing disorders at the Douglas Institute since 1990.

Serge Gauthier is credited with setting up the first multicentre Canadian study on the treatment of Alzheimer's Disease, using tacrine, as well as creating the Canadian Consortium of Centers for Clinical Cognitive Research (C5R). In addition to authoring countless research articles, reviews, and book chapters, Serge Gauthier has edited an internationally-cited textbook Clinical Diagnosis and Management of Alzheimer'Disease, with 50 percent Canadian authorship.

In 2001, Serge Gauthier co-chaired, with Christopher Patterson, MD, FRCPC, the Canadian Consensus Conference on Dementia (C3D), in order to develop evidence-based consensus statements on which to build clinical practice guidelines for primary care physicians toward the recognition, assessment, and management of dementing disorders. Serge Gauthier is famous for his outstanding contributions to the development of new diagnostic and therapeutic approaches to Alzheimer Disease and other dementing disorders.